Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Tongjitang Key Drug Flat in Q3

publication date: Nov 7, 2007
Tongjitang Chinese Medicines Company reported decent increases in both profits and revenues for its third quarter, but the results were in line with expectations, providing no upside surprises. The report also showed that sales for Xianling Gubao, the company’s flagship product, increased only 2% over the year-earlier quarter. Investors showed their disappointment in the Q3 report by pushing Tongjitang to a 15% loss. In mid-session, Tongjitang was off by $1.75 at $10.00. That price puts Tongjitang exactly back to the level of its IPO, which took place in March. More details...

Stock Symbol: (NYSE:TCM)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital